Neha Vapiwala on Muck Rack

Neha Vapiwala

As seen in: Color Research & Application, Nature, Wiley Online Library, PBS, JAMA Oncology, The Philadelphia Inquirer, STAT, HemOnc Today, Journal of Nuclear Medicine, OncoLink and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Neha

Contact Neha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

PROTEUS Pushes the Paradigm

|
By R. Jeffrey Karnes, Declan Murphy, Rana R. McKay, Neha Vapiwala, Steven Joniau
| European Urology Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Taplin ME, Gleave M, Shore ND, et al. Perioperative apalutamide in high-risk localized prostate cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2603878. 2. Ravi, P. ∙ Kwak, L. ∙ Acosta, A.M. ... Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer Eur Urol. 2025; 87:643-650 3. Devos, G. ∙ Giesen, A. ∙ Joniau, S.
Open in Who Shared Issue with article?

Highly Variable, Complex, and Contextual: The Business of Radiation Oncology Practice

|
By Vivek S. Kavadi, Neha Vapiwala
| International Journal of Radiation Oncology*Biology*Physics Verified
Get full text access Log in, subscribe or purchase for full access. REFERENCES 1. As of this Writing, the Most Recently-Available Medicare Data Are From 2024. MPFS Spend was $1.594B, and HOPPS was $2.619B 2. Lu, S.G. ∙ Sindhu, K.K. ∙ Rowley, J.P. Changes in employment and practice locations Among radiation oncologists: 2015-2023 Int J Radiat Oncol Biol Phys. 2025; 122:1095-1101 3. Shen, X. ∙ Showalter, T.N. ∙ Mishra, M.V. ...
Open in Who Shared Issue with article?

Safety of the Combination of External Beam Radiotherapy with 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer

|
By Abigail Pepin, Abigail Doucette, Neha Vapiwala, Vivek Narayan
| Journal of Nuclear Medicine Verified
The VISION trial of 177Lu-PSMA-617 (LuPSMA) demonstrated improved overall survival in patients with metastatic castration-resistant prostate cancer when compared with the best standard of care. The practice patterns for and safety of the combination of external beam radiotherapy (EBRT) and LuPSMA in the real-world setting are unknown. Here, we characterize the toxicities and efficacy of the combination of EBRT and LuPSMA among patients with metastatic castration-resistant prostate cancer.
Open in Who Shared Issue with article?
See all 23 licensed articles (27 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified